Introduction: A new treatment plan was
INTRODUCTION
Without intervention, even wealthy countries face a crisis in healthcare spending; escalating costs are driven, at least in part, by novel, high-cost biopharmaceuticals [1] . Sales of biopharmaceuticals currently amount to almost $70 billion in the US, and €60 billion in Europe [2, 3] . The expiration of patents for biopharmaceuticals allows pharmaceutical companies to develop and produce similar biological medicinal products, also known as biosimilars. The European Medicines Agency (EMA) defines biosimilars as medicines that are similar to a biological medicine that has already been approved [4] . 'Biosimilar' is therefore a regulatory term used to indicate a biopharmaceutical product that has been approved under a well-defined regulatory pathway. The principal reason for using biosimilar drugs is for cost saving [1] ; the uptake of biosimilars will therefore depend on the degree to which cost savings are required by healthcare systems and the absolute savings that could be gained by switching from original drugs.
A number of recombinant human growth hormone (rhGH) products are available for the treatment of pediatric growth disturbances, including somatropin (Omnitrope Pfizer, Sollentuna, Sweden) [5] . Omnitrope Ò is also approved in other territories including Australia, Canada, the Middle East, the Far East (e.g., Japan, Taiwan), Central and South America (e.g., Mexico, Argentina, Brazil), and has received positive opinion from the UK's National Institute for Health and Clinical Excellence (NICE) [6] . In addition, the product is approved for use in the [7] .
It is also approved for the treatment of adult GHD and, in the US, idiopathic short stature.
The availability of biosimilar medicines has potentially substantial benefits for healthcare providers and patients in terms of reducing drug expenditure and possibly increasing patient access to treatments [8] . In Sweden, almost all health care is publicly funded via taxes, and there is pressure to contain healthcare expenditure. 
METHODS

Implementation of the Switch to Biosimilar rhGH
A total of 120 patients were considered for a switch to treatment with biosimilar rhGH; 102 were finally offered a switch using a Dialogue Teamwork approach. Patients not offered the switch had an expected duration of further rhGH treatment \6 months (n = 16), or a history of allergic reaction to other growth hormone preparations (n = 2). All patients (or their parents) offered the switch were provided with the following information or support to aid their decision as part of the Dialogue
Teamwork approach:
• a letter from the Head of Department of Pediatrics explaining the economic rationale for the switch;
• the opportunity to discuss the medical aspects of the switch with the physician responsible for patient care;
• further dialogue with the Head of Department if patients did not accept the switch after the discussion with the responsible physician;
• information on the biosimilar rhGH (somatropin) from the EMA;
• a visit to a specialized endocrinology nurse to receive instructions on how to perform the switch (e.g., use the new device) and to ask any questions concerning the switch;
• the telephone number of the specialized endocrinology nurse to contact for advice.
The patients were familiar with the physician responsible for patient care and the specialized endocrinology nurse, the team that started the previous treatment with rhGH. Patients who still did not accept the switch were offered the opportunity to continue with the originator product by contributing the difference in cost of treatment between the originator and biosimilar rhGH. All treatments, visits, tests, and assessments were performed as part of routine clinical practice; no additional or specific visits, tests, or assessments were required as part of the study (except for the additional visit to the specialized nurse for patients/carers to receive instructions on use of the new device).
Ethics Approval
In Sweden, approval from an ethics committee 
Efficacy Assessments and Modeling Approach
Height and height standard deviation score (HSDS) data were plotted for each individual patient. In addition, a modeling approach was used for the statistical assessment of switchability to biosimilar rhGH. A logarithmic model for height had already been developed [10] . This model was used to fit the growth data before switching to biosimilar rhGH. More precisely, the fitted model was as follows:
where h ij is the height measured on child i and occasion j, t ij is the time from first visit in years, age 0i is the initial age, the as are fixed-effect parameters, the as and e are random (normal) terms.
This model was used to predict the individual growth trajectories after switching to biosimilar rhGH treatment; the predictions were then compared to the actual observed height after the switch to biosimilar rhGH. Table 1 ; the primary growth disturbance among these patients was GHD (n = 40; 41%). Six patients who switched to biosimilar rhGH reverted to their originator treatment; for three of these patients no height measurements are available for the period they were receiving biosimilar rhGH.
Height and HSDS data indicate no impact on growth velocity after patients were switched to treatment with biosimilar rhGH (Fig. 1) . Similarly, analysis of height data suggests no Turner syndrome 9
Prader-Willi syndrome 6
Small for gestational age 11
Other 36
a Four patients had dual diagnosis impact of the switch in each of the different growth disturbances (Fig. 2 ). The modeling approach described earlier was used to predict individual growth trajectories after switching treatments (Fig. 3) . The model was then used to compare the observed and predicted growth following the switch to biosimilar rhGH (Fig. 4) ; all data points lie close to the identity line 
DISCUSSION
This study indicates that Dialogue Teamwork can be successfully used to implement a switch from originator to biosimilar rhGH in children with growth disturbances. The switch to biosimilar rhGH had no impact on the children's growth and at the same time provided substantial cost and all money saved was retained by the clinic to spend elsewhere rather than being put back into the regional healthcare budget. An important factor in implementing the switch was ensuring patient adherence to therapy. Interventions to improve medical adherence typically focus on the motivation or attitudes of the individual patient or family [11] . However, a systematic review concluded that these approaches result in only modest improvements [12] . The interaction between the patient/family and the team of healthcare professionals was assessed using systematic techniques in order to identify and remove potential barriers to the switch from originator to biosimilar rhGH [13] [14] [15] . The focus of this study was then to change, through There is little published information on the impact of switching between GH products. switching between originator products, and assessed physician attitudes or the potential additional administration burden on clinics [16, 17] . In another study, using data from clinical trials, it was concluded that switching from originator to biosimilar rhGH had no impact on the efficacy and safety of treatment in children with GHD [10] . 
